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Abstract
The tight junction protein claudin-1 (CLDN1) is necessary for hepatitis C virus (HCV) entry into target cells. Recent studies
have made disparate observations of the modulation of the expression of CLDN1 on cells following infection by HCV. In one
study, the mean CLDN1 expression on cells exposed to HCV declined, whereas in another study HCV infected cells showed
increased CLDN1 expression compared to uninfected cells. Consequently, the role of HCV in modulating CLDN1 expression,
and hence the frequency of cellular superinfection, remains unclear. Here, we present a possible reconciliation of these
disparate observations. We hypothesized that viral kinetics and not necessarily HCV-induced receptor modulation underlies
these disparate observations. To test this hypothesis, we constructed a mathematical model of viral kinetics in vitro that
mimicked the above experiments. Model predictions provided good fits to the observed evolution of the distribution of
CLDN1 expression on cells following exposure to HCV. Cells with higher CLDN1 expression were preferentially infected and
outgrown by cells with lower CLDN1 expression, resulting in a decline of the mean CLDN1 expression with time. At the
same time, because the susceptibility of cells to infection increased with CLDN1 expression, infected cells tended to have
higher CLDN1 expression on average than uninfected cells. Our study thus presents an explanation of the disparate
observations of CLDN1 expression following HCV infection and points to the importance of considering viral kinetics in
future studies of receptor expression on cells exposed to HCV.
Citation: Padmanabhan P, Dixit NM (2012) Viral Kinetics Suggests a Reconciliation of the Disparate Observations of the Modulation of Claudin-1 Expression on
Cells Exposed to Hepatitis C Virus. PLoS ONE 7(4): e36107. doi:10.1371/journal.pone.0036107
Editor: Filippo Castiglione, National Research Council of Italy (CNR), Italy
Received December 9, 2011; Accepted March 30, 2012; Published April 24, 2012
Copyright:  2012 Padmanabhan, Dixit. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Department of Biotechnology Centre of Excellence for Research on Hepatitis C Virus, India. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: narendra@chemeng.iisc.ernet.in
Introduction
HCV entry into target cells is a multi-step process involving
interactions of the viral envelope proteins E1 and E2 with several
cell surface receptors, namely, scavenger receptor class B type I
(SR-BI) [1], the tetraspanin CD81 [2,3], and the tight junction
proteins claudin-1 (CLDN1) [4] and occludin [5] (reviewed in [6]).
Recent studies suggest a role of the CD81- CLDN1 receptor
complex in HCV entry [7–9]. Antibodies targeting the CD81-
CLDN1 interaction effectively blocked the entry of HCV,
including that of escape variants from patient sera [10,11]. The
host cofactors epidermal growth factor receptor (EGFR) and
ephrin receptor A2 (EphA2) mediate HCV entry through
regulation of the CD81-CLDN1 association [12]. CLDN1 also
appears to be necessary for cell-cell transmission of infection
[13,14]. Modulation of the expression of CLDN1 on cells is
expected therefore to alter the susceptibility of cells to HCV
infection.
Two recent studies examined CLDN1 expression on cells
exposed to HCV and made conflicting observations. Reynolds et
al. [15] found a significant increase in CLDN1 expression on
infected cells compared to uninfected cells, suggesting up-
regulation of CLDN1 after infection. In contrast, Liu et al. [16]
found that the mean CLDN1 expression on cells decreased
following HCV infection, suggesting down-modulation of CLDN1
after infection. The latter observation suggests a role for HCV-
mediated CLDN1 down-modulation in superinfection exclusion.
Superinfection exclusion is the process by which a cell once
infected becomes resistant to further infections, and has been
observed with HCV in vitro [16–18]. Cellular superinfection has
important implications in viral evolution via recombination and
may affect disease progression and the emergence of resistance to
direct acting antiviral agents [19], as observed with HIV [20–22].
The conflicting observations above leave unclear the influence of
HCV infection on CLDN1 expression and hence its role in
superinfection exclusion. Here, we present a possible reconciliation
of these conflicting observations.
We recognize that different cells in culture express different
levels of CLDN1 and may consequently be susceptible to HCV
infection to different extents. Cells with high CLDN1 expression
may be more readily infected than cells with low CLDN1
expression. At the same time, cells with high CLDN1 expression
may be outgrown by cells with low CLDN1 expression as the latter
cells may remain uninfected and proliferate unhindered by HCV.
The underlying viral kinetics may therefore skew the distribution
of CLDN1 expression on cells following exposure to HCV and
may explain the above conflicting observations. To test this
hypothesis, we employed a mathematical model of viral kinetics.
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provided valuable insights into disease pathogenesis and treatment
outcomes [19,23–36]. Recently, we constructed a mathematical
model of viral kinetics in vitro that quantitatively described several
independent observations of the dependence of HCV entry and
kinetics on the expression of CD81 on target cells and estimated
the minimum number of E2-CD81 complexes necessary for HCV
infection [37]. Here, we adapted our model to describe
experiments where cells with a known distribution of CLDN1
expression were exposed in culture to HCV and the resulting
changes in the distribution measured. We found, in agreement
with Reynolds et al. [15], that the preferential infection of cells
expressing high CLDN1 ensured that measurements yielded
higher CLDN1 expression on infected cells than uninfected cells.
At the same time, retarded growth of infected cells compared to
uninfected cells manifested as a shift of the overall CLDN1
expression in culture to lower levels as observed by Liu et al. [16].
Further, our model, without requiring active modulation of
CLDN1 by HCV, provided good fits to the latter data, suggesting
that the role of HCV-induced modulation of CLDN1 expression
in superinfection exclusion may require further examination.
Results
Model formulation
We considered in vitro experiments where a population of target
cells, T, with a known distribution of the CLDN1 expression level
was exposed to HCVcc (cell culture adapted) virions, V. The
distribution of CLDN1 expression on the target cells was well
described by a mixture of two log-normal distributions (Fig. 1). We
divided the target cells into different subpopulations Ti with
distinct CLDN1 expression levels ni, where i~1,2,...,K. We let
the dependence of the relative susceptibility of cells Ti to infection,
Si, on the CLDN1 expression, ni, be characterized by a Hill
function (Methods). Accordingly, Si increased with ni (Fig. 1).
Above a certain ni (<20 fluorescence units), CLDN1 expression
did not limit entry and cells were nearly completely susceptible
(Si&1). Below a certain ni (<5 fluorescence units), cells remained
refractory to infection (Si&0). Following exposure to HCV, cells
Ti were assumed to proliferate, die, and be infected at a rate
proportional to Si, yielding infected cells Ii. Infected cells were lost
at an enhanced rate compared to uninfected cells due to virus-
induced cytopathicity in vitro [38,39]. Free virions were produced
by infected cells and were cleared. We constructed dynamical
equations to describe the ensuing viral kinetics (Methods), which
we solved using parameter values representative of HCVcc
infection in vitro (Table 1).
Dependence of viral kinetics on CLDN1 expression
We found that infection proceeded in three phases (Fig. 2A). In
the first phase, the population of uninfected cells, T, rose because
of cell proliferation. Simultaneously, infection of cells by virions
resulted in the growth of infected cells, I (Fig. 2B). The viral titre,
V, declined initially as viral clearance dominated viral production
from the small population I (Fig. 2B). As I grew, viral production
increased and compensated viral clearance. V then evolved
proportionally to I, indicating the establishment of a pseudo-
steady state between viral production and clearance (Fig. 2B). The
growth of V increased the rate of infection of T; the loss of T due
to infection then became comparable to its growth by prolifera-
tion, so that, in the second phase, T exhibited a plateau (Fig. 2A).
Not all cells, however, were equally susceptible to infection. For
subpopulations with high CLDN1 expression (Si*1), infection
dominated proliferation. Accordingly, Ti for such subpopulations
declined leaving behind infected cells, Ii (see Si*1 in Fig. 2C).
The total subpopulation TizIi thus reached a plateau (Fig. 2D).
In contrast, for subpopulations with low CLDN1 expression,
proliferation dominated infection so that Ti continued to grow
(Si*0 in Fig. 2C) and the total subpopulation TizIi continuously
increased (Fig. 2D). Thus, in the third phase, T rose again (Fig. 2A)
due to the proliferation of the latter cells. I (and hence V)
Figure 1. Expression of CLDN1 on cells and their susceptibility
to infection. Best-fit (red line) of the normalized distribution of CLDN1
expression,
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where fmax is the maximum value of fn i ðÞ , to experimental data [16]
(red circles). The best-fit parameter estimates (95% CI) are
m1~1:24 1:23{1:25 ðÞ , s1~0:49 0:48-0:51 ðÞ , m2~1:74 1:62-1:86 ðÞ ,
s2~1:03 0:97-1:08 ðÞ , fmax~0:66 0:65-0:67 ðÞ , and x~0:64 0:58-0:69 ðÞ .
The corresponding susceptibility, Si, as a function of CLDN1 expression
is also shown (black line). (Inset) Residuals (symbols) of the best-fit to
experimental data; the mean error is 0:0001 and is not significantly
different from zero (line) (P~0:94 using the two tailed t-test).
doi:10.1371/journal.pone.0036107.g001
Table 1. Summary of model parameters and their values
employed.
Parameter Description Value (95% CI) Source
l Proliferation rate constant of
target cells
0.44 d
21 [37]
m Death rate constant of
target cells
1.7610
24 d
21 [37]
d Death rate constant of
infected cells
1.1610
22 d
21 [37]
b Infection rate constant of cells
with excess CLDN1 expression
1.2610
24 mlN(ffuNd)
21 [37]
p Viral production rate per
infected cell
2.78 ffuN(mlNd)
21 [37]
c Virion clearance rate constant 23.2 d
21 [37]
n50
i CLDN1 expression level at
which Si~0:5
33 (31–35)
fluorescence units
Best-fit
(Fig. 3)
h Hill coefficient 3.3 (3.0–3.6) Best-fit
(Fig. 3)
doi:10.1371/journal.pone.0036107.t001
Claudin-1 Expression Following HCV Infection
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e36107remained nearly constant in the third phase (Fig. 2B) as new
infections occurred rarely and the lifespan of infected cells
(*100 d) was much larger than the duration of the experiments
(5d ). This triphasic kinetics was analogous to the predictions of
our previous model and corresponding experiments where HCV
infection was limited by CD81 expression [37]. We examined next
whether this kinetics could reconcile observations of CLDN1
expression on cells following exposure to HCV.
Time-evolution of the distribution of CLDN1 expression
We found that following the onset of infection the overall
CLDN1 expression decreased with time, as observed by Liu et al.
[16] (Fig. 3). As a control, no change in the distribution was
observed in mock infected cells. Remarkably, our model provided
good fits to the measured distribution of CLDN1 expression on
cells at day 5 post-infection when the parameters h and n50
i , which
characterize the Hill function defining the susceptibility, were
adjustable. Note that no down-modulation of CLDN1 by HCV
was assumed. Cell subpopulations with high CLDN1 expression
reached a plateau by day 5 (Si&1 in Fig. 2D), whereas
subpopulations with low CLDN1 expression continued to
proliferate (Si&0 in Fig. 2D). Consequently, the latter cells
dominated the culture, explaining the shift in the CLDN1
distribution towards lower mean CLDN1 expression with time
(Fig. 3). This drop in the mean CLDN1 expression also explains
the observed resistance of the cells in culture at day 5 post-
infection to HCV pseudo-particle (HCVpp) entry [16].
Expression of CLDN1 on uninfected and infected cells
We found that the mean CLDN1 expression was greater on
infected cells than uninfected cells at any time post-infection
(Fig. 4A). This followed from the higher susceptibility to infection
of cells expressing more CLDN1. To mimic the observations of
Reynolds et al. [15], we randomly sampled twenty cells from the
infected and uninfected cell populations at different times post-
infection. We found that the average CLDN1 expression on the
infected cells sampled was higher than on the uninfected cells
sampled at all post-infection times considered (Fig. 4B), in
qualitative agreement with the observations of Reynolds et al.
[15] who reported data at day 3 post-infection. The difference
between the mean expression level of the samples became
significant with the progression of the infection (P=0.14 at day
1 and P=0.01 at day 3, using the one-tailed unequal variance
Students t-test on the data in Fig. 4B). Again, no active modulation
Figure 2. Model predictions of HCV viral kinetics in vitro. The time evolution of (A) uninfected cells, T, (B) infected cells, I, and viral load, V,
(C) uninfected cell subpopulations, Ti (solid line), and infected cell subpopulations, Ii (dashed line), corresponding to Si&0 (red) and 1 (cyan) and (D)
total subpopulations, TizIi, corresponding to Si&0 (red) and 1 (cyan). The three phases of infection are marked in (A). Initial conditions:
T(0)~2|105cells; I(0)~0cells; V(0)~2|104 ffu:ml
-1 (~0:1 MOI). Parameters employed are listed in Table 1.
doi:10.1371/journal.pone.0036107.g002
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with higher CLDN1 expression were more susceptible and hence
preferentially infected underlies the observed higher CLDN1
expression on infected cells than uninfected cells.
Discussion
Several recent in vitro studies have observed superinfection
exclusion with HCV [16–18], the mechanistic origins of which are
yet to be established. The superinfection block has been argued to
occur at the level of RNA replication and not at the level of virus
entry [17,18]. The block may also be due to genetic bottlenecks
associated with mitosis (Webster B, Wissing S, Herker E, Ott M,
and Greene W, presented at the 18
th International Symposium on
Hepatitis C Virus and Related Viruses, Seattle, Washington,
September 2011). More recently, Liu et al. [16] found that the
mean CLDN1 expression level on cells in culture decreased
following HCV infection suggesting that the superinfection block
could be at the level of entry and due to HCV-induced down-
modulation of CLDN1. Reynolds et al. [15] observed, however,
that CLDN1 expression on infected cells was higher than on
uninfected cells, suggesting an up-regulation of CLDN1 by HCV.
The role of HCV in modulating CLDN1 expression and hence
inducing a superinfection block at the level of virus entry thus
remained unclear. Here, we showed that the different susceptibil-
ities to infection of cells expressing different levels of CLDN1 and
the ensuing viral kinetics may render these conflicting observations
two sides of the same coin. Our model of viral kinetics without
requiring explicit modulation of CLDN1 expression by HCV fit
well the measured distribution of CLDN1 expression on cells
following exposure to HCV in vitro and also described the observed
higher CLDN1 expression on cells infected by HCV than those
uninfected. Thus, the HCV superinfection block in vitro may not be
due to HCV-induced down-modulation of CLDN1.
Although CLDN1 is required for HCV entry, its role in
mediating entry remains to be established. Only recently have
studies identified its association with CD81 as important for entry
[8–12]. Consequently, a mechanistic description of how the
susceptibility of cells to infection depends on CLDN1 expression
remains difficult to construct. Here, we have assumed, based on
our earlier model of the dependence of the susceptibility on CD81
expression [37], that the dependence of the susceptibility on
CLDN1 expression follows a Hill function (Methods). With this
assumption and without requiring explicit modulation of CLDN1
expression by HCV, our model fit the observed distribution of
CLDN1 expression at day 5 post-infection, giving us confidence in
our model. Yet, we cannot rule HCV-induced down-modulation
of CLDN1 out entirely, for it is conceivable that some down-
Figure 3. Evolution of the distribution of CLDN1 expression.
Model predictions (lines) of the normalized distribution of the CLDN1
expression on cells at day 1 (blue), day 3 (light green), and at day 5 (dark
green) post-infection, the latter fit to corresponding experimental data
[16] (green cricles). The best-fit parameter estimates are
n50
i ~33 (31{35) fluorescence units and h~3:3( 3 :0{3:6). The other
parameters employed are listed in Table 1. Initial conditions were the
same as in Fig. 2. Inset (A) shows the normalized distribution of CLDN1
expression on mock infected cells (V 0 ðÞ ~0) at all post-infection times
(lines overlap and are indistinguishable). Inset (B) shows the residual
(symbols) of the best-fit to the experimental data; the mean error is
0:0015 and is not significantly different from zero (line) (P~0:71 using
the two tailed t-test).
doi:10.1371/journal.pone.0036107.g003
Figure 4. Model predictions of CLDN1 expression on infected
and uninfected cells. (A) Time-evolution of the mean CLDN1
expression level on infected (orange) and uninfected (blue) cells. (B)
Average CLDN1 expression on twenty cells sampled from the infected
(orange) and uninfected (blue) populations at different post-infection
times. Error bars represent standard deviations. Parameters and initial
conditions employed were the same as in Fig. 2.
doi:10.1371/journal.pone.0036107.g004
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set of parameters that define the Hill function above would also fit
the observed distribution equally well. Indeed, Liu et al. showed
that coexpression of CLDN1 with the HCV proteins Core and
E1E2 in 293T cells inhibited CLDN1 expression [16]. The relative
extents of the explicit modulation of CLDN1 by HCV and the
shift in the distribution of CLDN1 expression due to the
underlying viral kinetics remain to be delineated fully. Infection
assays with growth-arrested cells [40,41] may facilitate this
delineation. The distribution of CLDN1 expression (or any entry
receptor) would remain unchanged post-infection on such cells if
there were no explicit modulation by HCV over times short
compared to the average life span of infected cells.
Our model assumed that CLDN1 alone limited HCV entry.
However, other receptors may also limit HCV entry. Indeed, in
the experimental distribution of CLDN1 expression at day 5 post
infection (Fig. 3), a tiny peak appears in the high CLDN1 region
possibly because here other entry receptors limit entry. Our model
thus did not capture this small peak. Our model was also limited to
a qualitative comparison with the experiments of Reynolds et al.
[15] because the distribution of CLDN1 expression on the Huh-
7.5 cell line they used was not known and a quantitative
relationship between measured fluorescence intensities and
CLDN1 expression remains to be established. Our aim was to
present a reconciliation of the disparities in the experimental
observations of the modulation of CLDN1 expression following
exposure to HCV, which our study accomplishes despite the above
limitations.
Importantly, our study points to the significance of considering
the underlying viral kinetics in interpreting data of receptor
expression following HCV infection. Several studies have argued
that HCV entry factors are down-modulated in HCV infected
cells. For instance, Liu et al. [16] have suggested that not only
CLDN1 but also occludin expression levels decreased post-
infection in their experiments. Sainz et al. [42] claimed down-
modulation of Niemann-Pick C1-like 1 (NPC1L1), a recently
identified HCV entry factor, following HCV infection. Our study
suggests that the observed reduction in the levels of entry receptors
could be due to the underlying viral kinetics and not necessarily
HCV-induced down-modulation of the receptors. Indeed, long-
term HCV infection in cell culture showed that the mean CD81
expression declined as CD81-low cells refractory to infection
outgrew CD81-high cells susceptible to infection [17,38] and the
cells infected allowed unhindered subsequent HCVpp entry
suggesting minimal HCV-induced down-modulation of CD81
[17]. Thus, whether HCV actively down-modulates entry
receptors remains to be established.
Methods
Initial CLDN1 expression on cells
We fit the distribution of CLDN1 expression on Huh7 cells [16]
using a mixture of two log-normal distributions, given by
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x
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where m1 and m2 were the means and s1 and s2 the standard
deviations of log10ni, and x was the mixture coefficient (Fig. 1). We
performed the fit using the nonlinear regression tool NLINFIT in
MATLAB and examined the goodness of fit by evaluating
residuals and characterizing them using the two-tailed t-test.
Dependence of the susceptibility on CLDN1 expression
Using reaction-equilibrium to estimate the mean number of E2-
CD81 complexes formed across a virus-cell contact and a Poisson
process to account for stochastic fluctuations, we previously
deduced the susceptibility of cells to infection, Si,t ob ea
sigmoidal function of CD81 expression [37]. CLDN1 is thought
not to interact directly with E2 but to mediate entry through its
association with CD81. Accordingly, we retained the sigmoidal
form and represented the dependence of Si on CLDN1 expression
using a Hill function, Si~
ni ðÞ
h
n50
i
   hz ni ðÞ
h, where h is the Hill
coefficient and n50
i is the CLDN1 expression level at which
Si~0:5. Note that Si&0 when ni&0 and Si&1 when niwwn50
i .
Model of HCV viral kinetics
We constructed a mathematical model of HCV kinetics in vitro,
where the susceptibility of a cell to infection was a function of its
CLDN1 expression level. Mimicking experiments, we considered a
population of target cells, T, with a known distribution of the
CLDN1 expression level across cells exposed to HCVcc virions.
We divided the cells into different subpopulations Ti with distinct
CLDN1 expression levels ni, where i~1,2,...,K. We let Si be the
relative susceptibility of cells Ti to infection. Cells Ti were assumed
to proliferate with the rate constant l, die with the rate constant m,
and be infected with the second order rate constant bSi, where b
represents the infection rate constant of cells expressing excess
CLDN1 (Si&1). The resulting infected cells, Ii, were lost with the
enhanced rate constant d due to HCV-induced cytopathicity
[38,39]. We neglected the proliferation of Ii as HCV induces cell
cycle arrest [39,43]. Free virions, V, were produced by Ii at the
rate p per cell and were cleared with the rate constant c. Here, c
represents the combined rate of the natural degradation of virions,
the loss of viral infectivity, and the loss of virions due to entry and
attachment [44,45]. The following coupled dynamical equations
then predicted the time-evolution of Ti, Ii, and V [37]:
dTi
dt
~ l{m ðÞ Ti{bSiTiV, i~1,2,::,K ð1Þ
dIi
dt
~bSiTiV{dIi, i~1,2,::,K ð2Þ
dV
dt
~p
X K
i~1
Ii{cV ð3Þ
Parameters
We solved the above equations using the initial distribution of
CLDN1 expression on Huh7 cells measured experimentally (Fig. 1)
[16]. We set the initial cell subpopulations to Ti(0)~f(ni)DniT(0),
where T(0) was the total initial target cell population and Dni was
the narrow range of CLDN1 expression that constituted each
subpopulation. We let Dlog10ni~0:05 and K~78; finer discre-
tisation did not alter our results [37]. We allowed h and n50
i to be
adjustable parameters and set the other model parameters
(l, m, d, p, c and b) to values that captured the dynamics of
infection of Huh-7.5 cells with the JFH-1 strain [37]. Model
parameters are summarized in Table 1.
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We considered data from recently published studies on the
modulation of CLDN1 expression following HCVcc infection
[15,16]. First, we considered the experiments of Liu et al. [16],
where Huh-7 cells were mock infected or exposed to JFH1 virions
(0.1 MOI) for 5 days. The total cellular CLDN1 expression level
was measured by western blotting and the cell surface expression
level was measured by flow cytometry (Fig. 4A and 4B in [16]). We
digitized data using Engauge digitizer. Using our model, we
predicted the distribution of CLDN1 expression at any time t post-
infection as fn i,t ðÞ ~ Ti t ðÞ zIi t ðÞ ðÞ
 
P K
i~1
Ti t ðÞ zIi t ðÞ ðÞ . We fit
model predictions of the latter distribution at day 5 to the above
data using the nonlinear regression tool NLINFIT in MATLAB.
We examined the goodness of fit by evaluating residuals and
characterizing them using the two-tailed t-test. We also repeated
the fits with different initial guesses of the adjustable parameters
and found that the fits remained unaltered.
Next, we considered the data of Reynolds et al. [15], where
Huh-7.5 cells were infected with JFH-1 virions and the average
CLDN1 expression on twenty cells from NS5A positive infected,
NS5A negative infected and uninfected populations were found at
day 3 post-infection (Fig. 6F in [15]). To mimic these observations,
we randomly sampled twenty cells each from the infected and
uninfected cells present at any time t and obtained the
corresponding mean and standard deviation of the CLDN1
expression levels on the sampled cells. The probability of choosing
a cell Ti from the population of uninfected cells was
Ti t ðÞ =
P K
i~1
Ti(t) and that of choosing a cell Ii from the population
of infected cells was Ii t ðÞ =
P K
i~1
Ii(t). We also computed the time-
evolution of the mean CLDN1 expression on all uninfected and
infected cells present in culture as
P K
i~1
niTi t ðÞ
 
P K
i~1
Ti t ðÞ and
P K
i~1
niIi t ðÞ
 
P K
i~1
Ii t ðÞ , respectively.
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